Section A: Strategies for Drug Discovery. -- 1. A Survey of Novel Molecular Targets for Anticancer Drug Discovery. -- 2. Microarrays: Small Spots Produce Major Advances in Pharmacogenomics. -- 3. Strategies to Target Chemotherapeutics to Tumors. -- 4. QSAR and Pharmacophore Mapping Strategies in Novel Anticancer Drug Discovery. -- 5. Applications of Nuclear Magnetic Resonance and Mass Spectrometry to Anticancer Drug Discovery. -- 6. Antisense Strategies for the Development of Novel Cancer Therapeutics. -- 7. Antibodies and Vaccines as Novel Cancer Therapeutics. -- 8. Inhibitors of Apoptosis (IAPs) as Targets for Cancer Therapy. -- 9. Preclinical Testing and Validation of Novel Anticancer Agents. -- Section B: Methods for Clinical Testing of Novel Agents. -- 10. Biologic Endpoints and Surrogate Markers for Ealry Trials of Novel Anticancer Agents. -- 11. Regulatory Considerations in Clinical Trials of Novel Anticancer Drugs. -- 12. Improving the Efficacy and Safety of Anticancer Agents -- The Role of Pharmacogenetics. -- 13. Imaging of Pharmacodynamic Endpoints in Clinical Trials. -- 14. Devising Proof of Concept Strategies in Oncology Clinical Trials. -- 15. Clinical Trial Designs for Cytostatic Agents and Agents Directed at Novel Molecular Targets. -- 16 Cancer Gene Therapy Clinical Trials: From the Bench to the Clinic. -- 17. Molecular Targest for Radiosensitization. -- 18. Patient Accrual to Clinical Trials.

A survey of novel molecular targets for anticancer drug discovery -- Microarrays: small spots produce major advances in pharmacogenomics -- Strategies to target chemotherapeutics to tumors -- QSAR and pharmacophore mapping strategies in novel anticancer drug discovery -- Applications of nuclear magnetic resonance and mass spectrometry to anticancer drug discovery -- Antisense strategies for the development of novel cancer therapeutics -- Antibodies and vaccines as novel cancer therapeutics -- Inhibitors as targets for cancer therapy -- Preclinical testing and validation of novel anticancer agents -- Surrogate end points and biomarkers for early trials of novel anticancer agents -- Regulatory considerations in clinical trials of novel anticancer drugs -- Improving the efficacy and safety of anticancer agents: the role of pharmacogenetics -- Imaging of pharmacodynamic end points in clinical trials -- Devising proof-of-concept strategies in oncology clinical trials -- Clinical trial designs for cytostatic agents and agents directed at novel molecular targets -- Cancer gene therapy clinical trials: from the bench to the clinic -- Molecular targets for radiosensitization -- Patient accrual to clinical trials.